Investor Presentation First Nine Months of 2022

76 Investor presentation First nine months of 2022 Protein and peptide expertise combined with oral technology enables oral amycretin entering phase 1 Amycretin is a GLP-1 and amylin receptor co-agonist intended for oral delivery Phase 1 single dose and multiple dose trial for oral amycretin in obesity initiated in 2022 GLP-1 receptor Novo NordiskⓇ People living with obesity, and Multiple ascending dose cohorts overweight or otherwise Single ascending dose cohorts healthy Trial objectives Amylin receptor • Assess the safety and tolerability of oral amycretin Utilising the SNAC technology PK: Pharmacokinetics; PD: Pharmacodynamics • Assess PK profile and explore PD effects Next steps • Phase 1 initiation Q2 2022

View entire presentation